Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation

Published:2017-09-16 Issue:5 Volume:57 Page:625-636
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Mizuno Kana,Dong Min,Fukuda Tsuyoshi,Chandra Sharat,Mehta Parinda A.,McConnell Scott,Anaissie Elias J.,Vinks Alexander A.

Funder

Mr. and Mrs. Sam Walton Research Award, University of Arkansas for Medical Sciences Medical Research Endowment

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/article/10.1007/s40262-017-0581-x/fulltext.html

Reference58 articles.

1. Marsh RA, Vaughn G, Kim MO, Li DD, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824–31.

2. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107(7):2633–8.

3. Marsh R, Fukuda T, Emoto C, Neumeier L, Khandelwal P, Chandra S, et al. Pre-transplant absolute lymphocyte counts impact the pharmacokinetics of alemtuzumab. Biol Blood Marrow Tranplant. 2017;23(4):635–41.

4. Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49(12):1457–65.

5. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006;38(7):501–6.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing high dose melphalan;Blood Reviews;2023-12

2. A rapid and sensitive LC-MS/MS method for simultaneous determination of melphalan and its monohydroxy and dihydroxy metabolites in human plasma;Journal of Chromatography B;2023-05

3. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation;The Journal of Clinical Pharmacology;2022-03-14

4. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens;Clinical Pharmacokinetics;2021-12-02

5. Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders;British Journal of Clinical Pharmacology;2021-06-13